Ponoi Management’s Nurix Therapeutics NRIX Stock Holding History

Ponoi Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$4.26M	Hold	327,123	–	–	5.82%	4
2022 Q2	$4.14M	Buy	327,123 +1	+0%	+$11	6.54%	4
2022 Q1	$4.58M	Hold	327,122	–	–	5.95%	4
2021 Q4	$9.47M	Sell	327,122 -234,451	-42%	-$7.11M	8.73%	4
2021 Q3	$16.8M	Sell	561,573 -124,701	-18%	-$3.85M	14.94%	4
2021 Q2	$18.2M	Hold	686,274	–	–	10.12%	5
2021 Q1	$21.3M	Hold	686,274	–	–	12.55%	5
2020 Q4	$22.6M	Buy	+686,274	New	+$22.7M	12.91%	5

Other funds holding NRIX

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ponoi Management's NRIX Position: Q3 2022 in Review

Ponoi Management held its Nurix Therapeutics (NRIX) position steady in Q3 2022 at 327,123 shares worth $4.26M. The position accounts for 5.82% of the portfolio, ranked #4.

Ponoi Management first reported a position in NRIX in Q4 2020 and has held it in 8 quarters since. The position peaked at $22.6M in Q4 2020. 118 funds tracked by Wall St. Rank hold NRIX as of Q3 2022.

Ponoi Management held 327,123 shares of Nurix Therapeutics worth $4.26M as of Q3 2022.
Ponoi Management left its Nurix Therapeutics share count unchanged in Q3 2022.
Nurix Therapeutics made up 5.82% of Ponoi Management's portfolio in Q3 2022, its #4 holding.
Ponoi Management first reported a position in Nurix Therapeutics in Q4 2020 and has held it in 8 quarters since.
Ponoi Management's Nurix Therapeutics position peaked at $22.6M in Q4 2020.
118 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2022.

Based on Ponoi Management's 13F filing for Q3 2022, filed 14 Nov 2022.